IRVING, Texas, July 31, 2025 (GLOBE NEWSWIRE) -- Sow Good Inc. (Nasdaq: SOWG) (“Sow Good” or “the Company”), a trailblazer in the freeze dried candy and treat industry, will hold a conference call on Thursday, August 14, 2025, at 10:00 a.m. Eastern time to discuss its results for the second quarter ended June 30, 2025. The Company will provide its financial results in a press release prior to the conference call. Date: Thursday, August 14, 2025Time: 10:00 a.m. Eastern timeRegistration Link: https://register ...

Company Participation - Seer, Inc. will participate in the Canaccord Genuity 45 Annual Growth Conference in Boston, MA [1] - The management is scheduled for a fireside chat on August 13 at 9:00 a.m. Eastern Time [2] Company Overview - Seer, Inc. is a pioneer in deep, unbiased proteomics, providing insights with unprecedented scale, speed, precision, and reproducibility [3] - The Proteograph Product Suite integrates proprietary engineered nanoparticles, streamlined automation, optimized consumables, and advanced analytical software [3] - Seer's technology addresses challenges faced by traditional proteomic methods, which often struggle with inconsistent data and limited throughput [3]

SAN JOSE, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- zSpace (Nasdaq: ZSPC) (“zSpace” or the “Company”), a leader in immersive learning, announced today that it plans to release financial results for the second quarter ended June 30, 2025, on Thursday, August 14, 2025, after the close of market trading. In conjunction with reporting second quarter 2025 results, zSpace will host a conference call at 5:00 p.m. ET / 2:00 p.m. PT with the Company’s Chief Executive Officer, Paul Kellenberger, and the Company’s Chi ...

EDINBURG, Va., July 31, 2025 (GLOBE NEWSWIRE) -- Shenandoah Telecommunications Company (“Shentel” or the “Company”) (Nasdaq: SHEN) announced second quarter 2025 financial and operating results. Second Quarter 2025 Highlights Glo Fiber Expansion Markets1 data subscribers grew 43.1% compared to the second quarter of 2024 to approximately 76,000. Glo Fiber Expansion Markets revenue grew 40.5% compared to the second quarter of 2024 to $19.8 million. Total revenue grew 3.2% compared to the second quarter of 2024 ...

Core Insights - Lincoln Educational Services Corporation's campuses in Melrose Park, IL and South Plainfield, NJ have been recognized as "America's Top Vocational Schools" for 2025 by USA Today, highlighting their commitment to student success and diversity [1][2] Group 1: Recognition and Commitment - The recognition as a top vocational school reflects Lincoln Tech's dedication to training essential workers in vital industries such as transportation, skilled trades, and healthcare support [2] - The award emphasizes Lincoln Tech's commitment to excellence in hands-on education, career readiness, and workforce development, with graduates acquiring high-demand skills that lead to employment opportunities [3][9] Group 2: Evaluation Criteria - The evaluation by USA Today and Statista was based on five main criteria: graduation rate, graduate salaries, diversity within the student body, anticipated years to pay off a program, and social mobility [2] - This is the inaugural year for USA Today to publish this list, indicating a new benchmark for vocational education recognition [2] Group 3: Campus Performance - The Melrose Park campus, established in 1902, reported that 75% of its graduates were hired in their field last year, with over 700 students graduating [3] - The South Plainfield campus also demonstrated strong hiring rates for graduates of its Diesel Service Technology, Heavy Equipment Technology, and Welding Technology programs, with nearly 200 students completing their training last year [4] Group 4: Company Overview - Lincoln Educational Services Corporation has been a leader in diversified career-oriented post-secondary education since 1946, offering programs in transportation, healthcare, skilled trades, and information technology [5][6] - The company operates 21 campuses across 12 states under three brands: Lincoln College of Technology, Lincoln Technical Institute, and Nashville Auto-Diesel College [6]

Core Insights - Facephi has launched a new feature called Advanced Injection Defense to enhance digital identity protection against deepfakes and manipulated media [1][2] - The feature integrates artificial intelligence and forensic image analysis to detect and block injection attacks, addressing the rising threat of digital identity fraud [2][4] Group 1: Company Overview - Facephi is a leading provider in the identity verification sector, focusing on verified digital identity solutions [1] - The company aims to restore trust in digital interactions by ensuring the authenticity of each step in the verification process [6] Group 2: Product Features - Advanced Injection Defense utilizes advanced detection methods for injection attacks, device emulation, and manipulation of capture channels [4] - The solution evaluates both visual content and the method of capture, identifying signs of alteration or simulation [4] Group 3: Market Relevance - The new feature is part of Facephi's Behavioral Biometrics solution and can be integrated into user onboarding and authentication processes [5] - It complies with regulatory standards and meets high-security requirements across various sectors, including banking, healthcare, telecommunications, and public administration [5]

Company Overview - J-Star Holding Co., Ltd. is a leading provider of innovative carbon fiber and composite solutions across various applications including personal sports equipment, healthcare products, automobile parts, resin systems, and research and development services [1][6] - The company has over 50 years of experience in the material composites industry, with operations in Taiwan, Hong Kong, and Samoa [6] Initial Public Offering (IPO) Details - J-Star announced the closing of its initial public offering of 1,250,000 ordinary shares at a price of $4.00 per share, resulting in gross proceeds of $5.0 million before expenses [1][2] - The shares began trading on the Nasdaq Capital Market under the symbol "YMAT" on July 30, 2025 [2] - Maxim Group LLC acted as the sole Book-Running manager for the offering and has been granted a 45-day option to purchase an additional 187,500 shares at the offering price [2][3] Regulatory Information - The offering was conducted under the Company's Registration Statement on Form F-1, which was declared effective by the U.S. Securities and Exchange Commission on July 29, 2025 [4]

Core Points - SeaStar Medical Holding Corporation has entered into a definitive agreement for the issuance and sale of 4,960,544 shares of common stock at a price of $0.887 per share, along with unregistered warrants to purchase an equal number of shares at an exercise price of $0.762 [1][2] - The gross proceeds from this offering are expected to be approximately $4.4 million, which will be used for general corporate purposes, including working capital and capital expenditures [2] - The offering is being conducted under a shelf registration statement previously filed with the SEC, and the shares are being offered only by means of a prospectus [3] Company Overview - SeaStar Medical is focused on transforming treatments for critically ill patients facing organ failure, with its first commercial product, QUELIMMUNE, approved by the FDA in 2024 for life-threatening acute kidney injury in pediatric patients [6] - The company’s Selective Cytopheretic Device (SCD) therapy has received Breakthrough Device Designation from the FDA for six therapeutic indications, which may facilitate faster approval and better reimbursement dynamics [6] - SeaStar Medical is currently conducting a pivotal trial of its SCD therapy in adult patients with acute kidney injury, a condition affecting over 200,000 adults in the U.S. annually [6]

Core Viewpoint - Alpine Banks of Colorado reported strong financial performance in the second quarter of 2025, with significant increases in net income and loan portfolio growth compared to previous periods [1][2]. Financial Performance - Net income for the second quarter of 2025 was $17.6 million, up from $14.3 million in the first quarter of 2025, marking a 23.1% increase [2][5]. - Year-to-date net income for the first half of 2025 reached $31.9 million, a 43% increase compared to $22.3 million in the first half of 2024 [2]. - Interest income rose by $3.0 million in the second quarter of 2025 compared to the first quarter, driven by higher yields and increased loan volume [2]. - Noninterest income increased by $0.7 million in the second quarter of 2025, primarily due to higher service charges and other income [2]. Loan Portfolio - Loans outstanding as of June 30, 2025, totaled $4.2 billion, reflecting a $87.0 million increase, or 2.1%, from the previous quarter [6]. - The growth in the loan portfolio was primarily driven by increases in commercial real estate loans ($81.8 million) and residential real estate loans ($77.0 million) [6]. - Year-over-year, loans outstanding increased by $145.7 million, or 3.6%, compared to $4.1 billion on June 30, 2024 [7]. Deposits - Total deposits decreased by $68.4 million, or 1.2%, to $5.9 billion during the second quarter of 2025, mainly due to declines in demand deposits and certificate of deposit accounts [8]. - However, total deposits increased by $76.6 million, or 1.3%, compared to $5.79 billion on June 30, 2024, driven by growth in money market accounts and demand deposits [9]. Capital and Ratios - The Bank maintained a "well capitalized" designation, with a Tier 1 Leverage Ratio of 9.90% and a Total Risk-Based Capital Ratio of 15.21% as of June 30, 2025 [12]. - Book value per share increased to $33.97 as of June 30, 2025, up by $1.03 from March 31, 2025 [13]. Dividends - The Company declared cash dividends of $0.21 per Class A and Class B common shares during the second quarter of 2025, payable on July 28, 2025 [14]. Company Overview - Alpine Banks of Colorado is an independent, employee-owned organization with total assets of $6.61 billion as of June 30, 2025, serving approximately 170,000 customers [15].

Core Viewpoint - PolTREG and its U.S. subsidiary Immuthera have received a positive opinion from the FDA regarding their adaptive Phase 2/3 trial of PTG-007 for presymptomatic Type 1 diabetes, indicating sufficient clinical data to support an IND application and outlining regulatory pathways to expedite U.S. development [2][3][4]. Group 1: FDA Feedback and Study Design - The FDA has acknowledged that PolTREG's clinical data in Stage 3 Type 1 Diabetes is adequate to support the potential benefits in an adaptive Phase 2/3 study for Stage 1 and Stage 2 presymptomatic patients [4][5]. - The FDA is open to including Stage 1 Polish patients in the trial's statistical analyses, which could lower costs and accelerate data readout [4][9]. - The proposed study design, which includes a double-blind format with four treatment groups and stratification by age and HLA, has been deemed reasonable by the FDA [5][9]. Group 2: Regulatory Pathways and Future Steps - PolTREG and Immuthera plan to apply for Fast Track, Breakthrough Therapy, or Regenerative Medicine Advanced Therapy (RMAT) designation in their IND filing, which could streamline the approval process [4][9]. - The company intends to file a formal IND meeting request with the FDA in the coming weeks to advance the trial [6]. Group 3: Company Overview and Strategic Developments - PolTREG is a leader in developing autoimmune therapies based on T-regulatory cells, with PTG-007 as its lead product for early-onset Type 1 Diabetes, currently ready for Phase 2/3 clinical testing [6]. - Immuthera is focused on developing cell-based therapies in the U.S. and Canada, leveraging PolTREG's R&D capabilities and asset pipeline [7]. - Recent strategic collaborations include partnerships with Noble Capital Markets, Inc. and Kinexum Services LLC to support U.S. registration efforts, as well as a collaboration with Antion Biosciences to develop next-generation allogeneic TREG therapies [9].